{
    "root": "4e1dfb0e-d523-48d2-8c82-c80ee2b49800",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Finasteride",
    "value": "20250219",
    "ingredients": [
        {
            "name": "FINASTERIDE",
            "code": "57GNO57U7G"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "DOCUSATE SODIUM",
            "code": "F05Q2T2JA0"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        }
    ],
    "indications": "Finasteride, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to (1.1): Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Finasteride administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) (1.2). Limitations of Use : Finasteride is not approved for the prevention of prostate cancer (1.3).",
    "contraindications": "Finasteride tablets may be administered with or without meals.",
    "warningsAndPrecautions": "Finasteride tablets USP, 5 mg are light green, oval, biconvex film coated tablets embossed with “R” on one side and “172” on the other side and are supplied in blistercards of 30 and 15.\n                  Blistercards of 30                                 NDC 0615-8562-39\n                  Blistercards of 15                                 NDC 0615-8562-05\n                  \n                     Storage and Handling \n                  Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Protect from light and keep container tightly closed.\n                  Females should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus [see Warnings and Precautions (5.3) and Use in Specific Populations (8.1)].",
    "adverseReactions": "Finasteride tablets are contraindicated in the following: \n                  \n                     Hypersensitivity to any component of this medication. \n                     Pregnancy. Finasteride use is contraindicated in females when they are or may potentially be pregnant. Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant females who receives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant females should be apprised of the potential hazard to the male fetus. [See also Warnings and Precautions  (5.3)\n                        \n                         , Use in Specific Populations  (8.1)\n                        , and How Supplied/Storage and Handling  (16)\n                        ]. In female rats, low doses of finasteride administered during pregnancy have produced abnormalities of the external genitalia in male offspring."
}